Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedSite revision updated to v3.5.0, replacing the prior v3.4.3.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page revision history shows removal of v3.4.1 and addition of v3.4.2; there are no changes to the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision badge updated from v3.4.0 to v3.4.1 on the page. No substantive content or functionality changes were detected.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to study content or user-facing features were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check110 days agoChange DetectedAn administrative revision tag 'Revision: v3.3.3' was added and the 'HHS Vulnerability Disclosure' link along with the previous 'Revision: v3.3.2' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.